Results of a 10-year follow-up study of botulinum toxin A therapy for primary axillary hyperhidrosis in Australia.

Internal medicine journal 2018 Vol.48(3) p. 343-347

Rosen R, Stewart T

관련 도메인

Abstract

Primary hyperhidrosis has a prevalence of 3-5% in the United States. It is a psychosocially disabling condition leading to low self-esteem, chronic stress and depressive symptoms. Several medical and surgical treatments exist, including botulinum toxin A, which internationally, has been shown effectively and safely to treat this condition achieving high patient satisfaction. In Australia, botulinum toxin A has been available under the Medicare benefits scheme for axillary hyperhidrosis since 2013, but efficacy and treatment satisfaction had not been evaluated. We present the results of the first Australian study on efficacy and patient satisfaction with botulinum toxin A in primary axillary hyperhidrosis with evaluation of possible prognostic factors.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 4

MeSH Terms

Acetylcholine Release Inhibitors; Adolescent; Adult; Aged; Botulinum Toxins, Type A; Cohort Studies; Female; Follow-Up Studies; Humans; Hyperhidrosis; Injections, Intradermal; Male; Middle Aged; New South Wales; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult

📑 인용 관계

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문